TP53 and lung adenocarcinoma: To determine whether the nanoplexes could be used to deliver single or dual-targeting siRNAs to lung adenocarcinomas in vivo, we took advantage of an aggressive transplantable model where tumors are generated in immunocompetent, syngeneic recipient animals by tail vein injection of K-RasG12D/+; p53−/− (KP7B) tumor cells31,32, followed by subsequent tumor seeding in the lung (Fig. 3d).